Grants and Contributions:

Back to search

Title:

IBE-814 IVT Diabetic Macular Edema and Retinal Vein Occlusion

Agreement Number:

986775

Agreement Value:

$810,564.00

Agreement Date:

Jan 1, 2022 - Jan 31, 2023

Description:

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on the development of Ripple’s lead product IBE-814 IVT for the treatment of Diabetic Macular Edema and Retinal Vein Occlusion. The project will require analysis of data generated from the ongoing clinical trial, and development and scale up of the product for the next stages on the path to commercialization.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Toronto, Ontario, CA M5G 1L7

Reference Number:

172-2021-2022-Q4-986775

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

760459073

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by -120 days. The total amended value is 60,564 dollars.

Amendment Date

Mar 1, 2023

Recipient's Operating Name:

Ripple Therapeutics

Recipient's Legal Name:

Ripple Therapeutics Corp.

Federal Riding Name:

University--Rosedale

Federal Riding Number:

35110

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

32541

Amendments:

See Amendments